Lymphoplasmacytic lymphoma classification: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(17 intermediate revisions by 3 users not shown)
Line 2: Line 2:
{{Lymphoplasmacytic lymphoma}}
{{Lymphoplasmacytic lymphoma}}


{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}{{S.M.}}
==Overview==
==Overview==
There is no established system for the classification of [disease name].
There is no established [[system]] for the [[classification]] of [[lymphoplasmacytic lymphoma]]. However, according to a devised [[criteria]] [[Based on Symptoms|based upon patient's symptoms]], [[Waldenström's macroglobulinemia]] can be further [[Classification|classified]] into smoldering/[[asymptomatic]] and [[symptomatic]] [[Waldenstrom macroglobulinemia]]([[Waldenström's macroglobulinemia|WM)]].  


OR
==Classification==
 
There is no established [[system]] for the [[classification]] of [[lymphoplasmacytic lymphoma]]. However, according to a devised [[criteria]] [[Based on Symptoms|based upon patient's symptoms]], [[Waldenström's macroglobulinemia]] can be further [[Classification|classified]] into:<ref name="pmid15735132">{{cite journal| author=Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP| title=Diagnosis and management of Waldenstrom's macroglobulinemia. | journal=J Clin Oncol | year= 2005 | volume= 23 | issue= 7 | pages= 1564-77 | pmid=15735132 | doi=10.1200/JCO.2005.03.144 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15735132  }} </ref>
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
 
OR
 
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3].
[Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
 
OR
 
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
 
OR
 
If the staging system involves specific and characteristic findings and features:
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
 
OR
 
The staging of [malignancy name] is based on the [staging system].


OR
*[[Symptomatic]] [[Waldenstrom macroglobulinemia]]
*[[Asymptomatic]]/Smoldering [[Waldenstrom macroglobulinemia]] (SWM)<ref name="pmid12720119">{{cite journal| author=Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M et al.| title=Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. | journal=Semin Oncol | year= 2003 | volume= 30 | issue= 2 | pages= 116-20 | pmid=12720119 | doi=10.1053/sonc.2003.50038 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12720119  }} </ref>


There is no established system for the staging of [malignancy name].
{|  
 
|+'''Classification of [[Waldenstrom macroglobulinemia]] (WM) and Related Disorders'''
==Classification==
There is no established system for the classification of Waldenström's macroglobulinemia. However, according to a devised criteria based upon patient's symptoms, it can be classified into:<ref name="pmid15735132">{{cite journal| author=Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP| title=Diagnosis and management of Waldenstrom's macroglobulinemia. | journal=J Clin Oncol | year= 2005 | volume= 23 | issue= 7 | pages= 1564-77 | pmid=15735132 | doi=10.1200/JCO.2005.03.144 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15735132  }} </ref>
*Symptomatic Waldenstrom macroglobulinemia.
*Asymptomatic/Smoldering Waldenstrom macroglobulinemia (SWM).<ref name="pmid12720119">{{cite journal| author=Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M et al.| title=Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. | journal=Semin Oncol | year= 2003 | volume= 30 | issue= 2 | pages= 116-20 | pmid=12720119 | doi=10.1053/sonc.2003.50038 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12720119  }} </ref>
{| class="wikitable"
|+ '''Classification of WM and Related Disorders'''
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptomatic WM
Line 44: Line 20:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS
|-
|-
| style="background:#DCDCDC;" align="center" + |IgM monoclonal protein
! align="center" style="background:#DCDCDC;" + |[[IgM monoclonal protein]]
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
|-
|-
| style="background:#DCDCDC;" align="center" + |Bone marrow infiltration
! align="center" style="background:#DCDCDC;" + |Bone marrow infiltration
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
|-
|-
| style="background:#DCDCDC;" align="center" + |Symptoms attributable to IgM
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to IgM
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
|-
|-
| style="background:#DCDCDC;" align="center" + |Symptoms attributable to tumor infiltration
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to tumor infiltration
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
|}
|}<br />


==References==
==References==
Line 73: Line 49:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category: (name of the system)]]
[[Category:Disease]]
[[Category:Blood]]
[[Category:Hematology]]

Latest revision as of 17:26, 8 April 2021

Lymphoplasmacytic lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lymphoplasmacytic Lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphoplasmacytic lymphoma classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphoplasmacytic lymphoma classification

CDC on Lymphoplasmacytic lymphoma classification

Lymphoplasmacytic lymphoma classification in the news

Blogs on Lymphoplasmacytic lymphoma classification

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Lymphoplasmacytic lymphoma classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Overview

There is no established system for the classification of lymphoplasmacytic lymphoma. However, according to a devised criteria based upon patient's symptoms, Waldenström's macroglobulinemia can be further classified into smoldering/asymptomatic and symptomatic Waldenstrom macroglobulinemia(WM).

Classification

There is no established system for the classification of lymphoplasmacytic lymphoma. However, according to a devised criteria based upon patient's symptoms, Waldenström's macroglobulinemia can be further classified into:[1]

Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders
Criteria Symptomatic WM Asymptomatic WM IgM-Related Disorders MGUS
IgM monoclonal protein + + + +
Bone marrow infiltration + + - -
Symptoms attributable to IgM + - + -
Symptoms attributable to tumor infiltration + - - -


References

  1. ↑ Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP (2005). "Diagnosis and management of Waldenstrom's macroglobulinemia". J Clin Oncol. 23 (7): 1564–77. doi:10.1200/JCO.2005.03.144. PMID 15735132.
  2. ↑ Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M; et al. (2003). "Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia". Semin Oncol. 30 (2): 116–20. doi:10.1053/sonc.2003.50038. PMID 12720119.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Lymphoplasmacytic_lymphoma_classification&oldid=1696578"